Evidence at a glance
Status and evidence table
| Peptide | Canada status | Human evidence |
|---|---|---|
| CJC-1295 | Not authorized in Canada | Limited: small or low-quality human studies |
| Ipamorelin | Not authorized in Canada | Very limited: almost all animal or cell studies |
| Sermorelin | Not authorized in Canada | Limited: small or low-quality human studies |
| Tesamorelin | Not currently marketed in Canada | Moderate: some randomized human trials, specific uses (HIV-associated abdominal fat) |
| GHRP-2 and GHRP-6 | Not authorized in Canada | Limited: small or low-quality human studies |
| Hexarelin | Not authorized in Canada | Limited: small or low-quality human studies |
| MK-677 (Ibutamoren) | Not authorized in Canada | Limited: small or low-quality human studies; one trial stopped for a safety signal |
Status reflects Health Canada's peptide pages, its April 2026 advisory and the Drug Product Database as checked on November 10, 2026. Authorized products carry an 8-digit DIN (drugs) or NPN (natural health products).
